{"version":"1.0","provider_name":"IFPMA","provider_url":"https:\/\/www.ifpma.org","title":"What role did regulatory agilities play during the COVID-19 pandemic and what can we learn from this experience? | IFPMA","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"CE7BfNtG3n\"><a href=\"https:\/\/www.ifpma.org\/insights\/what-role-did-regulatory-agilities-play-during-the-covid-19-pandemic-and-what-can-we-learn-from-this-experience\/\">What role did regulatory agilities play during the COVID-19 pandemic and what can we learn from this experience?<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.ifpma.org\/insights\/what-role-did-regulatory-agilities-play-during-the-covid-19-pandemic-and-what-can-we-learn-from-this-experience\/embed\/#?secret=CE7BfNtG3n\" width=\"600\" height=\"338\" title=\"&#8220;What role did regulatory agilities play during the COVID-19 pandemic and what can we learn from this experience?&#8221; &#8212; IFPMA\" data-secret=\"CE7BfNtG3n\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/06\/iStock-1156574440.jpg","thumbnail_width":2121,"thumbnail_height":1414,"description":"The COVID-19 pandemic has had a drastic impact on all the activities related to the development, assessment and approval of medicines and vaccines, unlocking opportunities to work in more agile and collaborative manners. Janis Bernat explains what we can learn from this experience."}